Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1Phase 2 1

Status

Withdrawn 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 2Genitourinary 2

Conditions

Lymphoma, Follicular 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Lymphoma 5Neoplasms 3Multiple Myeloma 3COVID-19 3Opioid-Related Disorders 2Lymphoma, Non-Hodgkin 2Leukemia, Myeloid, Acute 2Sezary Syndrome 1Recurrence 1Obesity 1Neurologic Manifestations 1Myelodysplastic Syndromes 1Lymphoma, T-Cell 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Biphenotypic, Acute 1Hematologic Neoplasms 1Genital Neoplasms, Female 1Dementia 1Criminal Behavior 1Colorectal Neoplasms 1Cognitive Dysfunction 1Breast Neoplasms 1Anomia 1Alzheimer Disease 1

Interventions

Standard of Care 3COH04S1 COVID-19 vaccine 2remdesivir 1palbociclib 1ogalvibart 1crexavibart 1cilgavimab and tixagevimab drug combination 1acalabrutinib 1XAV-19 1Therapeutics 1Surveys and Questionnaires 1Specimen Handling 1Rabeprazole 1Prednisone 1Methylprednisolone 1IBIO123 1Glucocorticoids 1Gelsolin 1Dexamethasone 1CVnCoV COVID-19 vaccine 1COVID-19 Vaccines 1COVID-19 Serotherapy 1Atorvastatin 13-(2-(2-tert-butylphenylaminooxalyl)aminopropionylamino)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid 11-palmityl-2-(4-carboxybutyl)-sn-glycero-3-phosphocholine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
COVID-19 × Standard of Care × Lymphoid × Clear all
NCT04904536 2025-04-10

STRONGER

The George Institute

Phase 3 Active not recruiting
190 enrolled
Lymphoid

COVID-19, Lymphoma, Follicular, Neurologic Manifestations

NCT04575064 2024-10-09

An International Randomized Trial of Additional Treatments for COVID-19 in Hospitalized Patients Who Are All Receiving the Local Standard of Care - WHO-SOLIDARITY-GERMANY

Klinikum Bremen-Mitte, gGmbH

Phase 2/3 Withdrawn
Lymphoid

COVID-19, Lymphoma, Follicular

NCT04733833 2023-02-01

A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With COVID-19

Vascular Biogenics Ltd. operating as VBL Therapeutics

Phase 2 Completed
5 enrolled
Lymphoid

COVID-19, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡